Vidac Pharma

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines to help people with a range of oncologic and dermatologic diseases. The companys technology targets the VDAC/HK2 system unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue. Vidacs lead drug, VDA-1102, has successfully completed a phase 2b clinical trial in actinic keratosis (AK) as an investigational new drug under the FDA and is currently in a phase 2a clinical trial in CTCL in Israel. The company is also developing VDA-1275, a potent small-molecule new chemical entity that selectively modulates the novel VDAC/HK2 mechanism of action. It is highly potent in vitro against a broad range of tumor types and demonstrates significant selectivity for the VDAC/HK2 system over the VDAC/HK1 system. VDA-1275 is chemically unrelated to VDA-1102 and presents a different set of pharmacokinetic characteristics. It is being developed as a systemic drug for the treatment of solid tumors. Vidac was founded by Professor Max Herzberg. The company has licensed part of its technology from Tel Aviv University and Ben Gurion University.

Vidac Pharma has raised $9M in total funding across 2 rounds. The company is currently at the Public stage. Key investors include Ed Saltzman, Mivtach Shamir Holdings, Israel Biotech Fund.

Vidac Pharma was founded in 2012 by Max Herzberg, Prof. (Founder, CEO & Active Chairman).

Vidac Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Vidac Pharma is based in Hartom Street 10, Jerusalem, Israel, Jerusalem District. The company also has offices abroad.